Thank you for your question on CMS506. The opioid medication list for the measure, Schedule II & III Opioid Medications (2.16.840.1.113762.1.4.1111.165) does not contain naloxone as a stand-alone medication. In version 5 of Safe Use of Opioids (2023), we removed all buprenorphine/naloxone combination medications from Schedule II & III Opioid Medications (2.16.840.1.113762.1.4.1111.165) as well. This value set, along with Schedule IV Benzodiazepines (2.16.840.1.113762.1.4.1125.1), is used to determine both the measure denominator and numerator. This means that naloxone and buprenorphine/naloxone combination medications do not count towards either the denominator, which requires patient discharge with at least one opioid or benzodiazepine, or towards the numerator. For example: 1) A patient discharged from an inpatient stay with naloxone and no other Schedule II or III opioids or benzodiazepines would not be in the initial patient population/denominator. 2) A patient discharged from an inpatient stay with naloxone and a benzodiazepine would be in the initial patient population/denominator. This is because the patient is discharged with a benzodiazepine. 3) A patient discharged from an inpatient stay with naloxone, methadone, and a benzodiazepine would be in the denominator and numerator because both methadone and the benzodiazepine count towards the numerator. Please see Schedule II & III Opioid Medications (2.16.840.1.113762.1.4.1111.165) and Schedule IV Benzodiazepines (2.16.840.1.113762.1.4.1125.1) to see which medications would qualify a patient encounter for the measure denominator and numerator and let us know if you have additional questions.